Why? Because Early Detection is Key.
Early detection aims to find the cancer in its early stages when treatment is most likely to be effective. The 5-year survival rate in the United States for men diagnosed with early-stage prostate cancer is greater than 99%.2
According to the American Cancer Society's 2019 data3, Black men are 60% more likely than white men to receive a diagnosis of prostate cancer and are twice as likely to die from the disease.
While genetics may play a role in Black men developing prostate cancer at a higher rate than other ethnicities (and developing it earlier in life), non-biological factors seem to drive the lower survival rate.
We know that we cannot stop Black men from developing prostate cancer. Still, we CAN provide the information and support to help shift the percentage of Black men dying from the disease. With this in consideration, Us TOO established a goal to reduce the Black/White prostate cancer survival gap in a targeted community.
The Black Men's Prostate Cancer Initiative's core goal is to even the playing field for prostate cancer survival rates through community outreach and education. We know it is a BIG goal, but we believe that open dialogue, early screening, community-wide education, and patient support can help save lives.
Based in Chicago, this pilot program seeks to create culturally appropriate tools and opportunities to facilitate prostate cancer dialogue in the Black community.
Thanks to the experts working with us to achieve our goals:
Us TOO is proud to be merging with ZERO – The End of Prostate Cancer. Learn more about ZERO’s Prostate Cancer Racial Disparities Task Force and the work they are doing to bring awareness of prostate cancer to high-risk men, strengthen existing early detection and education initiatives, and identify new ways to further address these issues in a consistent and impactful manner.
Want to help? Need more information? Please contact Rebecca at firstname.lastname@example.org or (773) 413-9197.
1Screening recommendations based on the National Comprehensive Cancer Network: https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1460